CEL-SCI (CVM) Competitors $0.62 -0.14 (-18.09%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CVM vs. CKPT, SCPH, VTYX, CDTX, ZURA, TCRX, NBTX, MCRB, FTLF, and ADAPShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Checkpoint Therapeutics (CKPT), scPharmaceuticals (SCPH), Ventyx Biosciences (VTYX), Cidara Therapeutics (CDTX), Zura Bio (ZURA), TScan Therapeutics (TCRX), Nanobiotix (NBTX), Seres Therapeutics (MCRB), FitLife Brands (FTLF), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Checkpoint Therapeutics scPharmaceuticals Ventyx Biosciences Cidara Therapeutics Zura Bio TScan Therapeutics Nanobiotix Seres Therapeutics FitLife Brands Adaptimmune Therapeutics CEL-SCI (NYSE:CVM) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher earnings and valuation, CVM or CKPT? CEL-SCI has higher earnings, but lower revenue than Checkpoint Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$32.19M-$0.58-1.18Checkpoint Therapeutics$47K4,322.24-$51.85M-$1.84-2.26 Does the media favor CVM or CKPT? In the previous week, Checkpoint Therapeutics had 17 more articles in the media than CEL-SCI. MarketBeat recorded 18 mentions for Checkpoint Therapeutics and 1 mentions for CEL-SCI. Checkpoint Therapeutics' average media sentiment score of 0.66 beat CEL-SCI's score of -1.32 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Checkpoint Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CVM or CKPT? CEL-SCI has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Does the MarketBeat Community prefer CVM or CKPT? Checkpoint Therapeutics received 179 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 67.29% of users gave Checkpoint Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes10100.00% Checkpoint TherapeuticsOutperform Votes17967.29% Underperform Votes8732.71% Do analysts rate CVM or CKPT? Checkpoint Therapeutics has a consensus price target of $10.33, suggesting a potential upside of 148.40%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in CVM or CKPT? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 14.1% of CEL-SCI shares are owned by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CVM or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -239.31% -102.69% Checkpoint Therapeutics N/A N/A -659.07% SummaryCheckpoint Therapeutics beats CEL-SCI on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$43.54M$2.98B$5.15B$19.68BDividend YieldN/A1.85%4.81%3.51%P/E Ratio-1.1847.02135.4243.79Price / SalesN/A420.451,184.6217.84Price / CashN/A182.1340.4221.73Price / Book2.443.944.895.48Net Income-$32.19M-$42.03M$118.71M$987.88M7 Day Performance1.84%-2.29%15.74%-2.00%1 Month Performance21.04%9.14%15.70%1.00%1 Year Performance-74.59%21.39%34.85%16.82% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.62-18.1%N/A-71.9%$39.56MN/A-1.0743Negative NewsGap UpHigh Trading VolumeCKPTCheckpoint Therapeutics3.8529 of 5 stars$3.41-7.1%$10.33+203.0%+11.9%$166.51M$100,000.00-1.8310Analyst ForecastOptions VolumeNews CoverageGap UpHigh Trading VolumeSCPHscPharmaceuticals3.6053 of 5 stars$3.30+3.4%$15.00+354.5%-43.2%$165.13M$13.59M-1.6830VTYXVentyx Biosciences3.3373 of 5 stars$2.31+1.3%$10.00+332.9%+5.3%$163.34MN/A-0.9773News CoverageCDTXCidara Therapeutics3.7721 of 5 stars$23.00+0.5%$32.20+40.0%+59.4%$162.15M$63.90M-0.9090Short Interest ↑ZURAZura Bio3.3088 of 5 stars$2.48+8.8%$15.80+537.1%-45.2%$161.92MN/A0.003TCRXTScan Therapeutics2.8129 of 5 stars$3.00+5.3%$11.25+275.0%-40.0%$160.11M$21.05M-2.69100NBTXNanobiotix1.6625 of 5 stars$3.33flat$12.00+260.4%-43.3%$156.95M$36.22M0.00100News CoverageGap UpMCRBSeres Therapeutics3.5788 of 5 stars$0.92+4.5%$5.08+453.6%-11.3%$156.79M$126.33M-4.04233News CoverageGap UpFTLFFitLife Brands3.219 of 5 stars$33.50-1.5%$40.00+19.4%+51.2%$154.03M$62.76M20.1220ADAPAdaptimmune Therapeutics1.5666 of 5 stars$0.59+1.7%$2.79+372.5%+33.2%$150.97M$60.28M-2.64449 Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors scPharmaceuticals Competitors Ventyx Biosciences Competitors Cidara Therapeutics Competitors Zura Bio Competitors TScan Therapeutics Competitors Nanobiotix Competitors Seres Therapeutics Competitors FitLife Brands Competitors Adaptimmune Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CVM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVM Stock Alerts